Trial Profile

A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tezepelumab (Primary)
Indications Churg-Strauss syndrome
Focus Therapeutic Use
Acronyms RACEMATE
Sponsors AstraZeneca

Most Recent Events

12 Apr 2024 Planned End Date changed from 1 Sep 2025 to 1 Oct 2025.
12 Apr 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Oct 2025.
12 Apr 2024 Planned initiation date changed from 1 Jan 2024 to 1 May 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com